CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
The new online Learning Center with new content can still be found under the “Training” folder on ...